Redu？？o da densidade de extrassístoles e dos sintomas relacionados após administra？？o de magnésio por via oral

background: premature ventricular and supraventricular complexes (pvc and psvc) are frequent and often symptomatic. the magnesium (mg) ion plays a role in the physiology of cell membranes and cardiac rhythm. objective: we evaluated whether the administration of mg pidolate (mgp) in patients with pvc and psvc is superior to placebo (p) in improving symptoms and arrhythmia frequency. methods: randomized double-blind study with 60 consecutive symptomatic patients with more than 240 pvc or psvc on 24-hour holter monitoring who were selected to receive placebo or mgp. to evaluate symptom improvement, a categorical and a specific questionnaire for symptoms related to pvc and psvc was made. improvement in premature complex density (pcd) per hour was considered significant if percentage reduction was >70% after treatment. the dose of mgp was 3.0 g/day for 30 days, equivalent to 260mg of mg element. none of the patients had structural heart disease or renal failure. results: of the 60 patients, 33 were female (55%). ages ranged from 16 to 70 years old. in the mgp group, 76.6% of patients had a pcd reduction >70%, 10% of them >50% and only 13.4% <50%. in the p group, 40% showed slight improvement, <30%, in the premature complexes frequency (p < 0.001). symptom improvement was achieved in 93.3% of patients in the mgp group, compared with only 16.7% in the p group (p < 0.001). conclusion: oral mg supplementation decreases pcd, resulting in symptom improvement.